Arctic Vision, a Chinese clinical-stage specialty ophthalmology company, today announced its US$32 million series A round financing led by Morningside Venture Capital, together with its existing investors Nan Fung Life Sciences and Pivotal BioVenture Partners China. Proceeds of the round will be used to gear up the clinical trials for ARVN001. ARVN001 is a proprietary […] Morningside Leads $32M Series A Round In Chinese Ophthalmology Firm Arctic Vision comes from China Money Network: Primary Data for China's Primary Markets! All Rights Reserved.